New options for medical therapy and risk scoring systems containing molecular data are
leading to increased complexity in the management of patients with myelofibrosis. To inform …

The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …

Close HLA matching of donors and recipients has been the dogma for successful allogeneic
blood or marrow transplantation (alloBMT), to limit the complications of graft-versus-host …

Haploidentical donors offer a potentially readily available donor, especially for non-White
patients, for hematopoietic cell transplantation (HCT). In this North American collaboration …

We evaluate the impact of donor types on outcomes of hematopoietic cell transplantation
(HCT) in myelofibrosis, using the Center for International Blood and Marrow Transplant …

TP53 mutations are present in up to 20% of patients with de novo myeloid neoplasms (MN)
and nearly 40% with myeloid neoplasm post cytotoxic therapy (MN-pCT). They are …

To develop a prognostic model for patients undergoing allogeneic hematopoietic cell
transplantation (allo-HCT) for myelofibrosis (MF), we examined the data of 623 patients …

Graft failure (GF) is a major complication of allogeneic hematopoietic cell transplantation
(alloHCT) that results in significant morbidity and mortality. Post-transplant …

Post-transplant cyclophosphamide (PTCy) allows safe and effective partially matched donor
allogeneic blood or marrow transplantation (alloBMT), so that almost everyone in need of …

Engraftment and nonrelapse mortality (NRM) after allogeneic hematopoietic cell
transplantation (allo-HCT) depend greatly on the transplantation platform in patients with …